Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Uterine Cervical Neoplasms × sitravatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Triple Negative Breast Neoplasms 2 Lung Neoplasms 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Melanoma 1 Lung Diseases 1 Liposarcoma 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Advanced Biliary Tract Cancer 1 Adenocarcinoma 1

Interventions

Cisplatin 56 Paclitaxel 25 Radiotherapy 24 Carboplatin 21 Bevacizumab 20 pembrolizumab 18 Brachytherapy 15 atezolizumab 9 Gemcitabine 9 camrelizumab 8 Topotecan 8 Nivolumab 8 Radiation 7 zimberelimab 6 tislelizumab 6 Docetaxel 6 Albumin-Bound Paclitaxel 6 toripalimab 5 nimotuzumab 5 lenvatinib 5 dostarlimab 5 Taxes 5 Papillomavirus Vaccines 5 Drug Therapy 5 Chemoradiotherapy 5 Cetuximab 5 durvalumab 4 Platinum 4 Magnetic Resonance Spectroscopy 4 Ipilimumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05614453 2023-06-29

ITTACC

Australia New Zealand Gynaecological Oncology Group

Phase 2 Withdrawn

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡